Humanigen (FRA:0KB2) Institutional Ownership : 2.57% (As of May. 31, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Humanigen Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Humanigen's institutional ownership is 2.57%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Humanigen's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Humanigen's Float Percentage Of Total Shares Outstanding is 89.59%.

Humanigen Institutional Ownership Historical Data

The historical data trend for Humanigen's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humanigen Institutional Ownership Chart

Humanigen Historical Data

The historical data trend for Humanigen can be seen below:

	2022-09-30	2022-10-31	2022-11-30	2022-12-31	2023-01-31	2023-02-28	2023-03-31	2023-04-30	2023-05-31	2023-06-30
Institutional Ownership	8.98	8.85	8.79	8.77	2.07	1.90	1.74	2.00	2.58	2.57

Humanigen Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Humanigen (FRA:0KB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (FRA:0KB2) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

HGENQ:USA

Address

830 Morris Turnpike, 4th Floor, Short Hills, NJ, USA, 07078

Website

https://www.humanigen.com

Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.

Humanigen (FRA:0KB2) Headlines

No Headlines